Drug news
Revlimid compared to investigators choice in Phase II/III DCL 001 trial for Diffuse Large B-Cell Lymphoma-Celgene
Celgene Corporation announced that results were presented from a phase II/III study (DLC-001) of Revlimid (lenalidomide) compared with investigators' choice (IC) of therapy in patients with relapsed/refractory diffuse large b-cell lymphoma (DLBCL) were presented during the 56th American Society of Hematology annual meeting. In this study, presented by Myron Czuczman , M.D., the data suggest improved response rates, progression-free survival and overall survival with lenalidomide compared with IC in the non-germinal b-cell (GCB) population as defined by immunohistochemistry (IHC). These improved outcomes appeared more pronounced in the activated b-cell (ABC) sub-type when assessed by gene expression profiling.